The importance of being NICE.
作者信息
Rid Annette, Littlejohns Peter, Wilson James, Rumbold Benedict, Kieslich Katharina, Weale Albert
机构信息
Department of Social Science, Health & Medicine, King's College London, Strand, London WC2R 2LS, UK
Department of Primary Care and Public Health Sciences, King's College London, Weston Street, London SE1 3QD, UK.
出版信息
J R Soc Med. 2015 Oct;108(10):385-9. doi: 10.1177/0141076815598877. Epub 2015 Oct 2.
Abstract
摘要
相似文献
1
The importance of being NICE.
J R Soc Med. 2015 Oct;108(10):385-9. doi: 10.1177/0141076815598877. Epub 2015 Oct 2.
2
Health technology assessment - an important opportunity to inform the use of medical devices in the paediatric population: an analysis of NICE Medical Technology Guidance.
Appl Health Econ Health Policy. 2023 Jul;21(4):533-535. doi: 10.1007/s40258-023-00805-9. Epub 2023 May 6.
3
Redaction at the heart of NICE appraisals.
Drug Ther Bull. 2023 Sep;61(9):130. doi: 10.1136/dtb.2023.000035. Epub 2023 Jul 31.
4
NICE: mostly a bad idea.
Emerg Med J. 2009 Sep;26(9):627-8. doi: 10.1136/emj.2009.072132.
5
Data briefing. NICE (National Institute for Clinical Excellence).
Health Serv J. 2000 Jun 8;110(5708):32.
6
Searching for a threshold - Not so NICE..
J Health Serv Res Policy. 2007 Jul;12(3):190; author reply 190-1. doi: 10.1258/135581907781543058.
7
NICE appraisals should be everybody's business.
BMJ. 2007 May 5;334(7600):936-8. doi: 10.1136/bmj.39190.420081.94.
8
NICE and new: appraising innovation.
BMJ. 2010 Jan 5;340:b5493. doi: 10.1136/bmj.b5493.
9
Adopting medical technologies and diagnostics recommended by NICE: the Health Technologies Adoption Programme.
Ann R Coll Surg Engl. 2014 Jul;96(5):400-1. doi: 10.1308/rcsann.2014.96.5.400.
10
NICE work--providing guidance to the British National Health Service.
N Engl J Med. 2004 Sep 30;351(14):1383-5. doi: 10.1056/NEJMp048221.
引用本文的文献
1
Justice, Transparency and the Guiding Principles of the UK's National Institute for Health and Care Excellence.
Health Care Anal. 2022 Jun;30(2):115-145. doi: 10.1007/s10728-021-00444-y. Epub 2021 Nov 8.
2
NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
Health Care Anal. 2020 Sep;28(3):193-227. doi: 10.1007/s10728-019-00381-x.
3
Innovation as a value in healthcare priority-setting: the UK experience.
Soc Justice Res. 2019;32(2):208-238. doi: 10.1007/s11211-019-00333-9. Epub 2019 Apr 15.
4
National Institute for Health and Care Excellence, social values and healthcare priority setting.
J R Soc Med. 2019 May;112(5):173-179. doi: 10.1177/0141076819842846. Epub 2019 Apr 2.
5
Swiss-CHAT: Citizens Discuss Priorities for Swiss Health Insurance Coverage.
Int J Health Policy Manag. 2018 Aug 1;7(8):746-754. doi: 10.15171/ijhpm.2018.15.
6
Priority Setting: Right Answer to a Far Too Narrow Question? Comment on "Global Developments in Priority Setting in Health".
Int J Health Policy Manag. 2018 Jan 1;7(1):86-88. doi: 10.15171/ijhpm.2017.66.
本文引用的文献
1
Public Reasoning and Health-Care Priority Setting: The Case of NICE.
Kennedy Inst Ethics J. 2017;27(1):107-134. doi: 10.1353/ken.2017.0005.
2
National Institute for Clinical Excellence: NICE works.
J R Soc Med. 2015 Jun;108(6):211-9. doi: 10.1177/0141076815587658.
3
Regulation of the pharmaceutical industry: promoting health or protecting wealth?
J R Soc Med. 2015 Jun;108(6):220-2. doi: 10.1177/0141076814568299. Epub 2015 Apr 28.
4
Beyond political rhetoric to new ideas for a sustainable NHS.
Lancet. 2015 Jan 24;385(9965):303. doi: 10.1016/S0140-6736(15)60099-X.
5
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi. doi: 10.3310/hta19140.
6
Assessment and approval of drugs to be reviewed in the UK.
Lancet Oncol. 2014 Nov;15(12):e530. doi: 10.1016/s1470-2045(14)70321-3. Epub 2014 Sep 26.
7
Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?
Health Econ. 2015 Jan;24(1):1-7. doi: 10.1002/hec.3130.
8
Cancer charity demands extension of drug fund despite criticisms it is unfair.
BMJ. 2014 Oct 28;349:g6507. doi: 10.1136/bmj.g6507.
9
The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.
Health Econ. 2015 Oct;24(10):1256-1271. doi: 10.1002/hec.3086. Epub 2014 Sep 23.
10
Which way now for the Cancer Drugs Fund?
BMJ. 2014 Sep 9;349:g5524. doi: 10.1136/bmj.g5524.
Zotero 插件